Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen

REFERENCES

• Wingo PA, Tong T, Bolden S. Cancer statistics, 1995 [published erratum appears in CA Cancer J Clin 1995; 45(2): 127-8]. CA Cancer J Clin 1995; 45: 8–30.
   Google Scholar
• Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–16.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer [published erratum appears in N Engl J Med 1991; 325(18): 1324] [see comments]. N Engl J Med 1991; 324: 1156— 61.
   Google Scholar
• Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan 0. A complex between prostate-specific antigen and alpha 1-antichymo-trypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222–6.
   Google Scholar
• Christensson A, Bjork T, Nilsson 0, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA, Lilja H. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100–5.
   Google Scholar
• Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH. Measurement of the complex between prostate-specific antigen and alpha 1-protease inhibitor in serum [see com-ments]. Clin Chem 1999; 45: 814–21.
   Google Scholar
• Chen Z, Chen H, Stamey TA. Prostate specific antigen in benign pro static hyperplasia: purifica-tion and characterization. J Urol 1997; 157: 2166–70.
   Google Scholar
• Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, Wolfert RL, Saedi MS. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997; 50: 710–4.
   PubMed Web of Science ®Google Scholar
• Lilja H, Oldbrink J, Rannevik G, Laurell C-B. Seminal vesicle secreted proteins and their reac-tions during gelation and liquefaction of human semen. J Clin Invest 1987; 80: 281–5.
   Google Scholar
• Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific anti-gen. J Natl Cancer Inst 1999; 91: 1635–40.
   PubMed Web of Science ®Google Scholar
• Yoshida E, Ohmura S, Sugiki M, Maruyama M, Mihara H. Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int J Cancer 1995; 63: 863–5.
   Google Scholar
• Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993; 192: 940–7.
   PubMed Web of Science ®Google Scholar
• Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75: 1046–53.
   PubMed Web of Science ®Google Scholar
• Owens RA, Gesellchen PD, Houchins BJ, DiMarchi RD. The rapid identification of HIV protease inhibitors through the synthesis and screening of defined peptide mixtures. Biochem Biophys Res Commun 1991; 181: 402–8.
   PubMedGoogle Scholar
• Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990; 249: 386–90.
   PubMed Web of Science ®Google Scholar
• Felici F, Castagnoli L, Musacchio A, Jappelli R, Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol 1991; 222: 301–10.
   Google Scholar
• Doorbar J, Winter G. Isolation of a peptide antagonist to the thrombin receptor using phage display. J Mol Biol 1994; 244: 361–9.
   PubMed Web of Science ®Google Scholar
• Koivunen E, Wang B, Dickinson CD, Ruoslahti E. Peptides in cell adhesion research. Methods Enzymol 1994; 245: 346–69.
   PubMed Web of Science ®Google Scholar
• Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988; 67: 31–40.
   PubMed Web of Science ®Google Scholar
• Leinonen J, Lovgren T, Vornanen T, Stenman UH. Double-label time-resolved immunofluoro-metric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clin Chem 1993; 39: 2098–103.
   PubMed Web of Science ®Google Scholar
• Giebel LB, Cass RT, Milligan DL, Young DC, Arze R, Johnson CR. Screening of cyclic peptide phage libraries identifies ligands that bind strepta-vidin with high affinities. Biochemistry 1995; 34: 15430— 5.
   Google Scholar
• Robert M, Gibbs BF, Jacobson E, Gagnon C. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/ semenogelin I. Cancer 1997; 79: 1370–80.
   Google Scholar
• Lovgren J, Airas K, Lilja H. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extra-cellular protease inhibitors. Eur J Biochem 1999; 262: 781–9.
   Google Scholar
• Katz BA, Clark JM, Finer-Moore JS, Jenkins TE, Johnson CR, Ross MJ, Luong C, Moore WR, Stroud RM. Design of potent selective zinc-mediated serine protease inhibitors. Nature 1998; 391: 608–12.
   Google Scholar
• Berg JM, Shi Y. The galvanization of biology: a growing appreciation for the roles of zinc. Science 1996; 271: 1081–5.
   PubMed Web of Science ®Google Scholar
• Berg JM, Godwin HA. Lessons from zinc-binding peptides. Annu Rev Biophys Biomol Struct 1997; 26: 357–71.
   PubMedGoogle Scholar
• Fisher RJ, Fivash M. Surface plasmon resonance based methods for measuring the kinetics and binding affinities of biomolecular interactions. Curr Opin Biotechnol 1994; 5: 389–95.
   Google Scholar
• Feng S, Kasahara C, Rickles RJ, Schreiber SL. Specific interactions outside the proline-rich core of two classes of Src homology 3 ligands. Proc Natl Acad Sci USA 1995; 92: 12408–15.
   PubMed Web of Science ®Google Scholar
• Pierce HH, Schachat F, Brandt PW, Lombardo CR, Kay BK. Identification of troponin C antagonists from a phage-displayed random pep-tide library. J Biol Chem 1998; 273: 23448–53.
   Google Scholar
• Lundwall A. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem Biophys Res Commun 1989; 161: 1151–9.
   PubMed Web of Science ®Google Scholar
• Stenman UH, Paus E, Allard WJ, Andersson I, Andres C, Barnett TR, Becker C, Belenky A, Bellanger L, Pellegrino CM, Bormer OP, Davis G, Dowell B, Grauer LS, Jette DC, Karlsson B, Kreutz FT, van der Kwast TM, Lauren L, Leinimaa M, Leinonen J, Lilja H, Linton HJ, Nap M, Hilgers J, et al. Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 1999; 20: 1–12.
   Google Scholar
• Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE. Genera-tion of angiostatin-like fragments from plasmino-gen by prostate-specific antigen. Br J Cancer 1999; 81: 1269–73.
   PubMed Web of Science ®Google Scholar